Literature DB >> 25153393

Analysis of androgen and anti-androgen regulation of KLK-related peptidase 2, 3, and 4 alternative transcripts in prostate cancer.

John Lai, Jiyuan An, Colleen C Nelson, Melanie L Lehman, Jyotsna Batra, Judith A Clements.   

Abstract

We assessed whether alternative transcripts (using KLK2, KLK3 and KLK4 as models) are differentially regulated by androgens and anti-androgens as an indicator of prostate cancers as they acquire treatment resistance. Using RNAseq of LNCaP cells treated with dihydrotestosterone, bicalutamide and enzalutamide, we show that the expression of variant KLK transcripts is markedly different to other variant transcripts at those loci. We also reveal that KLK variants are also over 2-fold more highly expressed in prostate cancers compared to their corresponding normal prostate. We propose that androgens and anti-androgens can activate specific variant transcripts of critical prostate cancer genes during treatment resistance.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25153393     DOI: 10.1515/hsz-2014-0149

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  9 in total

1.  Pseudogenes as Biomarkers and Therapeutic Targets in Human Cancers.

Authors:  Cristina Sisu
Journal:  Methods Mol Biol       Date:  2021

2.  Fusion transcript loci share many genomic features with non-fusion loci.

Authors:  John Lai; Jiyuan An; Inge Seim; Carina Walpole; Andrea Hoffman; Leire Moya; Srilakshmi Srinivasan; Joanna L Perry-Keene; Chenwei Wang; Melanie L Lehman; Colleen C Nelson; Judith A Clements; Jyotsna Batra
Journal:  BMC Genomics       Date:  2015-12-01       Impact factor: 3.969

3.  Discovery of Bladder Cancer-related Genes Using Integrative Heterogeneous Network Modeling of Multi-omics Data.

Authors:  Chen Peng; Ao Li; Minghui Wang
Journal:  Sci Rep       Date:  2017-11-15       Impact factor: 4.379

4.  A microsatellite repeat in PCA3 long non-coding RNA is associated with prostate cancer risk and aggressiveness.

Authors:  John Lai; Leire Moya; Jiyuan An; Andrea Hoffman; Srilakshmi Srinivasan; Janaththani Panchadsaram; Carina Walpole; Joanna L Perry-Keene; Suzanne Chambers; Melanie L Lehman; Colleen C Nelson; Judith A Clements; Jyotsna Batra
Journal:  Sci Rep       Date:  2017-12-04       Impact factor: 4.379

5.  Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients.

Authors:  Weiwei Gong; Yueyang Liu; Christof Seidl; Tobias Dreyer; Enken Drecoll; Matthias Kotzsch; Holger Bronger; Julia Dorn; Viktor Magdolen
Journal:  PLoS One       Date:  2019-02-27       Impact factor: 3.240

6.  SWATH-MS Based Proteomic Profiling of Prostate Cancer Cells Reveals Adaptive Molecular Mechanisms in Response to Anti-Androgen Therapy.

Authors:  Chamikara Liyanage; Adil Malik; Pevindu Abeysinghe; Judith Clements; Jyotsna Batra
Journal:  Cancers (Basel)       Date:  2021-02-09       Impact factor: 6.639

7.  KLK4 Induces Anti-Tumor Effects in Human Xenograft Mouse Models of Orthotopic and Metastatic Prostate Cancer.

Authors:  Brian W-C Tse; Thomas Kryza; Mei-Chun Yeh; Ying Dong; Kamil A Sokolowski; Carina Walpole; Tobias Dreyer; Johanna Felber; Jonathan Harris; Viktor Magdolen; Pamela J Russell; Judith A Clements
Journal:  Cancers (Basel)       Date:  2020-11-24       Impact factor: 6.639

8.  Prognostic value of kallikrein-related peptidase 7 (KLK7) mRNA expression in advanced high-grade serous ovarian cancer.

Authors:  Weiwei Gong; Yueyang Liu; Eleftherios P Diamandis; Marion Kiechle; Holger Bronger; Julia Dorn; Tobias Dreyer; Viktor Magdolen
Journal:  J Ovarian Res       Date:  2020-10-21       Impact factor: 4.234

9.  A four-gene signature associated with clinical features can better predict prognosis in prostate cancer.

Authors:  Penghui Yuan; Le Ling; Qing Fan; Xintao Gao; Taotao Sun; Jianping Miao; Xianglin Yuan; Jihong Liu; Bo Liu
Journal:  Cancer Med       Date:  2020-09-13       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.